No Data
No Data
Outperforming the Large Cap in the past 4 months! Hong Kong stocks for Innovative Drugs are gaining strength again, with Institutions expecting that the pharmaceutical main theme may run through the entire year.
① Hong Kong stocks of Innovative Drugs are strengthening again, which Bullish catalysts are Institutions focusing on? ② The Biomedical Index has outperformed the Large Cap for the past four months; how strong has its performance been this year?
AI empowers the FDA! Drug approvals hit the 'fast-forward' button, and a large number of pharmaceutical companies may welcome a 'Gold' period.
The USA Food and Drug Administration (FDA) announced an accelerated plan on Thursday to fully implement AI applications across all subsidiary institutions by June 30, aiming to significantly expedite the approval process for new pharmaceuticals.
CANBRIDGE-B: 2024 ANNUAL REPORT
In the performance report, Beihai Kangcheng (01228.HK) reported a full-year loss that expanded to 0.443 billion yuan.
Beihai Kangcheng - B (01228.HK) announced its 2024 annual results, with revenue recorded at 85.1 million yuan (the same below), a year-on-year decline of 17.3%. Loss expanded from 0.379 billion yuan in the previous year to 0.443 billion yuan, with a loss per share of 1.04 yuan. No final dividend is declared.
CANBRIDGE-B (01228) released its annual performance, with a Shareholder attributable loss of 0.443 billion yuan, an increase of 16.84% year-on-year.
CANBRIDGE-B (01228) announced its annual results for the year ending December 31, 2024, with the group achieving revenues...
CANBRIDGE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024